OnKure Therapeutics (NASDAQ:OKUR) Upgraded to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of OnKure Therapeutics (NASDAQ:OKUR) to a strong-buy rating in a research note released on Thursday morning, Zacks.com reports.

Separately, Oppenheimer started coverage on shares of OnKure Therapeutics in a research note on Thursday. They set an outperform rating and a $35.00 price target for the company.

OnKure Therapeutics Stock Up 2.7 %

OKUR stock opened at $19.00 on Thursday. The firm has a market cap of $63.46 million, a PE ratio of -1.13 and a beta of 0.21. OnKure Therapeutics has a 52-week low of $9.80 and a 52-week high of $87.20.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.